WO1991004058A3 - Treatment of conditions and disease - Google Patents
Treatment of conditions and disease Download PDFInfo
- Publication number
- WO1991004058A3 WO1991004058A3 PCT/CA1990/000306 CA9000306W WO9104058A3 WO 1991004058 A3 WO1991004058 A3 WO 1991004058A3 CA 9000306 W CA9000306 W CA 9000306W WO 9104058 A3 WO9104058 A3 WO 9104058A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- treated
- hyaluronic acid
- treatment
- conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU4895848/A RU2146139C1 (en) | 1989-09-21 | 1990-09-18 | Medical care of states and diseases, combinations and compositions usable in medicine, method and combinations for stimulating activity of macrophages |
DE69024039T DE69024039T3 (en) | 1989-09-21 | 1990-09-18 | USE OF HYALURONIC ACID IN COMBINATION WITH ASCORBIC ACID, ANTITUARY AGENTS AND / OR NSAIDS FOR TREATING CANCER |
RO148511A RO112812B1 (en) | 1989-09-21 | 1990-09-18 | Method of treating diseases or health states and composition for treatment |
BR909006924A BR9006924A (en) | 1989-09-21 | 1990-09-18 | FORMULATION FOR THE TREATMENT OF SYMPTOMS AND DISEASES, USE OF FORMULATION FOR THE TREATMENT OF SYMPTOMS AND DISEASES, METHOD FOR THE TREATMENT OF SYMPTOMS AND DISEASES, DISTRIBUTION OF MEDICINAL AND THERAPEUTIC AGENTS FOR THE TREATMENT OF SYMPTOMS AND DISEASES IN COMBINATION |
US07/675,908 US6069135A (en) | 1989-09-21 | 1990-09-18 | Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents |
DK90914108T DK0445255T4 (en) | 1989-09-21 | 1990-09-18 | Use of hyaluronic acid in combination with ascorbic acid, antitumor agents and / or NSAIDs for the treatment of cancer |
EP90914108A EP0445255B2 (en) | 1989-09-21 | 1990-09-18 | USE OF HYALURONIC ACID IN COMBINATION WITH ASCORBIC ACID, ANTITUMOUR AGENTS AND/OR NSAIDs FOR TREATING CANCER |
KR1019910700514A KR920700697A (en) | 1989-09-21 | 1990-09-18 | Method for treating tumor-related diseases in mammals using complex consisting of drug for treating disease and hyaluronic acid |
NO91911952A NO911952L (en) | 1989-09-21 | 1991-05-21 | TREATMENT OF CONDITIONS AND DISEASES AND AGENTS THEREOF. |
FI912470A FI912470A0 (en) | 1989-09-21 | 1991-05-21 | BEHANDLING AV HAELSOTILLSTAOND OCH SJUKDOMAR. |
US08/290,848 US5910489A (en) | 1990-09-18 | 1993-02-16 | Topical composition containing hyaluronic acid and NSAIDS |
US08/462,615 US5830882A (en) | 1989-09-21 | 1995-06-05 | Compositions containing a form of hyaluronic acid and a medicinal agent for treating acne in mammals and methods for administration of such composition |
US08/466,778 US5962433A (en) | 1990-09-18 | 1995-06-06 | Topical composition containing hyaluronic acid and NSAIDS |
US08/468,329 US5824658A (en) | 1990-09-18 | 1995-08-07 | Topical composition containing hyaluronic acid and NSAIDS |
HK44797A HK44797A (en) | 1989-09-21 | 1997-04-10 | Treatment of conditions and disease |
US10/628,999 US20040019011A1 (en) | 1989-09-21 | 2003-07-28 | Treatment of conitions and disease |
US11/245,816 US20060128655A1 (en) | 1989-09-21 | 2005-10-07 | Use of hyaluronic acid or its derivatives to enhance delivery of antineoplastic agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA000612307A CA1340994C (en) | 1989-09-21 | 1989-09-21 | Treatment of conditions and disease |
CA612,307 | 1989-09-21 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US83867492A Continuation-In-Part | 1990-09-18 | 1992-02-21 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/675,908 Continuation-In-Part US6069135A (en) | 1989-09-21 | 1990-09-18 | Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents |
US08/467,994 Continuation-In-Part US6218373B1 (en) | 1992-02-20 | 1995-06-06 | Formulations containing hyaluronic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1991004058A2 WO1991004058A2 (en) | 1991-04-04 |
WO1991004058A3 true WO1991004058A3 (en) | 1991-09-19 |
Family
ID=4140639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1990/000306 WO1991004058A2 (en) | 1989-09-21 | 1990-09-18 | Treatment of conditions and disease |
Country Status (26)
Country | Link |
---|---|
US (14) | US6069135A (en) |
EP (2) | EP0656213B1 (en) |
JP (1) | JP3256761B2 (en) |
KR (1) | KR920700697A (en) |
CN (1) | CN1101228C (en) |
AP (1) | AP175A (en) |
AT (2) | ATE227587T1 (en) |
AU (3) | AU6433090A (en) |
BR (1) | BR9006924A (en) |
CA (2) | CA1340994C (en) |
DE (2) | DE69024039T3 (en) |
DK (2) | DK0656213T3 (en) |
ES (2) | ES2186693T3 (en) |
FI (1) | FI912470A0 (en) |
HK (2) | HK44797A (en) |
HU (2) | HU220758B1 (en) |
IL (1) | IL95745A (en) |
IN (1) | IN171745B (en) |
LT (1) | LT3545B (en) |
NO (1) | NO911952L (en) |
RO (1) | RO112812B1 (en) |
RU (1) | RU2146139C1 (en) |
SG (1) | SG49658A1 (en) |
SK (1) | SK459890A3 (en) |
WO (1) | WO1991004058A2 (en) |
ZA (1) | ZA907564B (en) |
Families Citing this family (237)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
AU7312291A (en) * | 1990-02-13 | 1991-09-03 | Gere S. Dizerega | Peritoneal induced medicaments |
US5639738A (en) * | 1992-02-20 | 1997-06-17 | Hyal Pharmaceutical Corporation | Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs |
CA2061566C (en) * | 1992-02-20 | 2002-07-09 | Rudolf E. Falk | Treatment of disease employing hyaluronic acid and nsaids |
CA2061703C (en) * | 1992-02-20 | 2002-07-02 | Rudolf E. Falk | Formulations containing hyaluronic acid |
WO1992006714A1 (en) * | 1990-10-18 | 1992-04-30 | Shiseido Co., Ltd. | Combination of hyaluronic acid with medicinal ingredient and production thereof |
US5733891A (en) * | 1990-10-18 | 1998-03-31 | Shiseido Co., Ltd. | Compound for medicinal ingredient and hyaluronic acid and process for producing the same |
US5629287A (en) * | 1991-01-18 | 1997-05-13 | University College London | Depot formulations |
US5610148A (en) * | 1991-01-18 | 1997-03-11 | University College London | Macroscopically oriented cell adhesion protein for wound treatment |
US5416071A (en) * | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
EP0503583A1 (en) * | 1991-03-12 | 1992-09-16 | Takeda Chemical Industries, Ltd. | Composition for sustained release of erythropoietin |
US6432405B1 (en) * | 1991-03-15 | 2002-08-13 | Duke University | Method of inhibiting HIV infection with CD44 and anti-CD44 antibodies |
WO1994007505A1 (en) * | 1991-07-03 | 1994-04-14 | Norpharmco Inc. | Use of hyaluronic acid and forms to prevent arterial restenosis |
CA2122519C (en) * | 1994-04-29 | 2001-02-20 | Rudolf Edgar Dr. Falk | Cancer treatment and metastasis prevention |
US6022866A (en) * | 1991-07-03 | 2000-02-08 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
US5990095A (en) * | 1991-07-03 | 1999-11-23 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
US5817644A (en) * | 1991-07-03 | 1998-10-06 | Hyal Pharmaceutical Corporation | Targeting of dosages of medicine and therapeutic agents |
CA2079205C (en) * | 1992-09-25 | 1998-02-10 | Rudolf Edgar Falk | Use of hyaluronic acid and forms to prevent arterial restenosis |
EP0522491B1 (en) * | 1991-07-10 | 1998-11-18 | Takeda Chemical Industries, Ltd. | Compositions based on hyaluronic acid |
FR2686899B1 (en) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
CA2061567C (en) * | 1992-02-20 | 1998-02-03 | Rudolf E. Falk | Use of hyaluronic acid to repair ischemia reperfusion damage |
CA2130762C (en) * | 1994-08-24 | 1999-07-06 | Eva Anne Turley | Treatment of disease and conditions associated with macrophage infiltration |
US5438075A (en) | 1993-03-30 | 1995-08-01 | Skubitz; Keith M. | Oral glutamine to reduce stomatitis |
CA2094203A1 (en) * | 1993-04-16 | 1994-10-17 | Derek A. Willoughby | Inhibition of angiogenesis |
ATE502664T1 (en) * | 1993-07-19 | 2011-04-15 | Angiotech Pharm Inc | METHOD OF PRODUCTION OF A STENT WITH ANTI-ANGIOGENIC COMPOSITION |
HUT76846A (en) * | 1994-08-30 | 1997-12-29 | Hyal Pharma Corp | Hyaluronic acid and derivatives for modulation of cellular activity |
US6492332B1 (en) | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
US7091181B2 (en) | 1994-12-12 | 2006-08-15 | Omeros Corporation | Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors |
AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
ES2377126T3 (en) * | 1994-12-12 | 2012-03-22 | Omeros Corporation | Irrigation solution and use thereof for perioperative inhibition of pain, inflammation and / or spasms in a vascular structure |
KR100517210B1 (en) * | 1994-12-12 | 2006-06-07 | 오메로스 코포레이션 | Infusion solution for pain, inflammation and spasm |
CA2154103C (en) * | 1995-07-18 | 1998-02-24 | Samuel Simon Asculai | Treatment of mucous membrane disease, trauma or condition and for the relief of pain |
US6013641A (en) * | 1995-09-28 | 2000-01-11 | Sangstat Medical Corporation | Use of hyaluronic acid as an immunosuppressant |
CN1209068A (en) * | 1995-10-23 | 1999-02-24 | 海欧制药澳大利亚有限公司 | Hyaluronic acid as DNA carrier for gene therapy and VEGF antisense DNA to treat abnormal retinal vascularization |
US5652273A (en) * | 1995-11-30 | 1997-07-29 | Henry; James | Reduction of hair growth |
WO1997020564A1 (en) * | 1995-12-01 | 1997-06-12 | Hyal Pharmaceutical Corporation | Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags) |
US6413961B1 (en) | 1995-12-12 | 2002-07-02 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
CA2166155C (en) * | 1995-12-27 | 2008-02-05 | Eva Anne Turley | Agents binding to hyaluronic acid binding domains and the use thereof |
AU732344B2 (en) * | 1996-01-11 | 2001-04-12 | Jagotec Ag | Oral administration of effective amounts of forms of hyaluronic acid |
US6875753B1 (en) | 1996-03-14 | 2005-04-05 | The Governors Of The University Of Alberta | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
US20050101564A1 (en) * | 1996-04-02 | 2005-05-12 | Pilarski Linda M. | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) |
US5939047A (en) * | 1996-04-16 | 1999-08-17 | Jernberg; Gary R. | Local delivery of chemotherapeutic agents for treatment of periodontal disease |
US6787530B1 (en) * | 1996-08-23 | 2004-09-07 | Monash University | Use of pregnane-diones as analgesic agents |
WO1998013024A2 (en) * | 1996-09-27 | 1998-04-02 | Hyal Pharmaceutical Corporation | Hyaluronic drug delivery system |
US6451784B1 (en) * | 1996-12-30 | 2002-09-17 | Battellepharma, Inc. | Formulation and method for treating neoplasms by inhalation |
CA2205692A1 (en) * | 1997-05-16 | 1998-11-16 | Hyal Pharmaceutical Corporation | Method of administration for a therapeutic agent utilizing suitable forms of hyaluronic acid and combinations with electroporation |
CA2205771C (en) * | 1997-05-22 | 2002-05-14 | Hyal Pharmaceutical Corporation | Improved delivery of disease modifiers |
US6123957A (en) * | 1997-07-16 | 2000-09-26 | Jernberg; Gary R. | Delivery of agents and method for regeneration of periodontal tissues |
US5938658A (en) * | 1997-12-02 | 1999-08-17 | Tu; Hosheng | Device and methods for treating canker sores by RF ablation |
US7070799B1 (en) | 1998-02-10 | 2006-07-04 | Generex Pharmaceuticals, Inc. | Method for administering insulin to the buccal region |
US6017545A (en) * | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
BR9909393A (en) | 1998-04-03 | 2000-12-26 | Ajinomoto Kk | Antitumor agent, use of a stilbene derivative and a platinum coordination compound, and, process for the treatment or improvement of a tumor |
US7799766B2 (en) * | 1998-04-08 | 2010-09-21 | Theta Biomedical Consulting & Development Co., Inc. | Composition for treating hormonally-dependent cancers |
US6984667B2 (en) * | 1998-04-08 | 2006-01-10 | Theta Biomedical Consulting And Development Co. | Synergistic proteoglycan compositions for inflammatory conditions |
GB9810127D0 (en) * | 1998-05-13 | 1998-07-08 | Ml Lab Plc | Prevention of surgical adhesions |
US6391861B1 (en) | 1998-05-14 | 2002-05-21 | The Trustees Of Columbia University In The City Of New York | Method for the prevention of tissue elastic fiber injury |
US6663874B2 (en) | 1998-11-02 | 2003-12-16 | Victor Stevens | Composition to alleviate pain and topical method of applying same |
AU2101800A (en) * | 1998-12-23 | 2000-07-31 | Esparma Gmbh | Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis |
NZ512676A (en) * | 1999-01-13 | 2003-01-31 | Meditech Res Ltd | A composition and method for the enhancement of the efficacy of drugs |
AU773984B2 (en) * | 1999-01-13 | 2004-06-10 | Alchemia Oncology Pty Limited | A composition and method for the enhancement of the efficacy of drugs |
JP2002536323A (en) * | 1999-02-04 | 2002-10-29 | ジェンザイム コーポレーション | Prevent abscess formation |
ATE441425T1 (en) * | 1999-02-26 | 2009-09-15 | Maas Biolab Llc | CEREBROSPINAL AND VASCULAR PHARMACEUTICAL PREPARATION AND METHOD FOR THE PRODUCTION THEREOF |
JP4698843B2 (en) * | 1999-05-17 | 2011-06-08 | エーザイ インコーポレイテッド | Improved cellular uptake of bioactive agents |
JP4450456B2 (en) * | 1999-09-27 | 2010-04-14 | 株式会社マルハニチロ水産 | Sebum production inhibitor |
SE9904121D0 (en) * | 1999-11-15 | 1999-11-15 | Gustaf Jederstroem | Hydrophobic biomolecular structure |
EP1867718B1 (en) * | 1999-12-13 | 2010-01-20 | Bioniche Life Sciences Inc. | Therapeutically useful synthetic oligonucleotides |
EP1250152B1 (en) * | 1999-12-28 | 2013-05-15 | Bioniche Urology IP Inc. | Synergistic composition containing hyaluronic acid in the treatment of cancer |
GB0003048D0 (en) * | 2000-02-11 | 2000-03-29 | Dealler Stephen F | The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism |
ES2206363T3 (en) | 2000-04-07 | 2004-05-16 | Laboratoire Medidom S.A. | OPHTHALMIC FORMULATIONS BASED ON CYCLOSPORINE, Hyaluronic Aid and POLYSORBATE. |
ES2529300T3 (en) * | 2000-04-12 | 2015-02-18 | Novozymes Biopharma Dk A/S | Albumin fusion proteins |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AU5702201A (en) * | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
CA2410577A1 (en) * | 2000-05-23 | 2001-12-13 | The Trustees Of Columbia University In The City Of New York | Method for treating respiratory disorders associated with pulmonary elastic fiber injury |
US6221166B1 (en) * | 2000-06-07 | 2001-04-24 | Simplus Systems Corporation | Multi-thermal zone shielding apparatus |
AU9407501A (en) * | 2000-06-23 | 2002-04-22 | Medigenes | Agent for reduction of scar formation by using wound alkalinization |
US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
AUPQ879500A0 (en) * | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
US7285284B2 (en) * | 2000-09-08 | 2007-10-23 | Kuhnau Stephen C | Cosmetic composition, method of use and method of making |
WO2002026239A1 (en) * | 2000-09-26 | 2002-04-04 | Temple University Of The Commonwealth System Of Higher Education | Analgesic and glucosamine compositions |
US6924273B2 (en) * | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
HUP0303719A2 (en) * | 2000-10-16 | 2004-03-01 | Neopharm, Inc. | Liposomal pharmaceutical composition of mitoxantrone and process for their preparation |
EP1343502A2 (en) * | 2000-11-17 | 2003-09-17 | Idenix (Cayman) Limited | Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
CN1131036C (en) * | 2001-02-28 | 2003-12-17 | 中国人民解放军第三军医大学 | Application of N-acetyl-D-aminoglucose in preparing medicines to suppress by-effect of radiotherapy and chemicotherapy |
US20060198815A1 (en) * | 2001-03-19 | 2006-09-07 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained release |
US20020172712A1 (en) * | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
EP1383376A4 (en) * | 2001-03-19 | 2006-03-08 | Praecis Pharm Inc | Pharmaceutical formulations for sustained release |
JP5024497B2 (en) * | 2001-03-27 | 2012-09-12 | キユーピー株式会社 | Oral skin improving agent, skin improving method and food composition for skin improvement |
US8403954B2 (en) | 2001-05-22 | 2013-03-26 | Sanostec Corp. | Nasal congestion, obstruction relief, and drug delivery |
EP1401477A4 (en) * | 2001-05-25 | 2005-02-02 | Human Genome Sciences | Chemokine beta-1 fusion proteins |
US20030027867A1 (en) * | 2001-06-29 | 2003-02-06 | Myriad Genetics, Incorporated | Use of R-NSAID compounds for anti-HIV treatment |
CA2456966A1 (en) | 2001-08-14 | 2003-02-27 | Tel Aviv University Future Technology Development Lp | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
US20050042303A1 (en) * | 2001-08-27 | 2005-02-24 | Brown Tracey Jean | Therapeutic protocols |
AU2002325635C1 (en) * | 2001-08-27 | 2008-09-25 | Alchemia Oncology Pty Limited | Improved therapeutic protocols |
US7354910B2 (en) * | 2001-10-18 | 2008-04-08 | Seikagaku Kogyo Kabushiki Kaisha | Agent for treating inflammatory bowel diseases |
EP1443944A1 (en) * | 2001-11-12 | 2004-08-11 | Johannes Reinmüller | Pharmaceutical applications of hyaluronic acid preparations |
US6806259B2 (en) | 2001-12-21 | 2004-10-19 | Soft Gel Technologies, Inc. | Hyaluronic Acid in soft gel form |
EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
RU2213557C2 (en) * | 2001-12-26 | 2003-10-10 | Закрытое акционерное общество "Аксис" | Pharmaceutical composition eliciting thrombolytic, anti-inflammatory and cytoprotective properties |
US7993390B2 (en) * | 2002-02-08 | 2011-08-09 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US6887270B2 (en) | 2002-02-08 | 2005-05-03 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US8506647B2 (en) * | 2002-02-14 | 2013-08-13 | Boston Scientific Scimed, Inc. | System for maintaining body canal patency |
CA2476451A1 (en) * | 2002-02-15 | 2003-08-28 | Research Development Foundation | Hyaluronic acid mediated adenoviral transduction |
FR2836336B1 (en) | 2002-02-26 | 2004-08-27 | Diana Ingredients | USE IN A COSMETIC TREATMENT OF A PHENOLIC FRACTION RICH IN DIHYDROCHALCONES |
DE60313754T2 (en) * | 2002-03-06 | 2008-01-24 | The Medical Research and Education Trust, San Diego | BOTANICAL EXTRACT WITH ANTICIPATIVE ACTIVITY INCLUDING ISOLIQUIRITIGENIN |
KR100518152B1 (en) * | 2002-05-09 | 2005-09-29 | 메디제네스(주) | A Pharmaceutical Composition for Treatment of Wounds Containing Blood Plasma or Serum |
ITMI20020986A1 (en) * | 2002-05-10 | 2003-11-10 | Acraf | COMPOSITION BASED ON DICLOFENAC FOR THE TOPICAL TREATMENT OF AFFECTIONS OF THE OROPHARINGOUS CABLE |
CA2491054A1 (en) * | 2002-07-03 | 2004-01-15 | Pericor Science, Inc. | Compositions of hyaluronic acid and methods of use |
ES2405287T3 (en) * | 2002-08-01 | 2013-05-30 | Eisai Inc. | Improved treatment of glutamine cancer |
US6660308B1 (en) | 2002-09-11 | 2003-12-09 | Kenneth A. Martin | Beverage and additive for the ill |
US20040254095A1 (en) * | 2002-09-11 | 2004-12-16 | Martin Kenneth A. | Supplement for treating musculoskeletal disorders |
US6900173B2 (en) * | 2002-09-11 | 2005-05-31 | Kenneth A. Martin | Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery |
US20040253296A1 (en) * | 2002-09-11 | 2004-12-16 | Martin Kenneth A. | Food bar for treating musculoskeletal disorders |
US20040253227A1 (en) * | 2002-09-11 | 2004-12-16 | Martin Kenneth A. | Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery |
US6979458B1 (en) | 2002-09-11 | 2005-12-27 | Kenneth A. Martin | Beverage and additive for wellness |
DE10246340A1 (en) * | 2002-10-04 | 2004-04-29 | Wohlrab, David, Dr. | Combination preparation of hyaluronic acid and at least one local anesthetic and its use |
EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | Method and composition for treating neurodegenerative disorders |
US20080063677A1 (en) * | 2004-03-10 | 2008-03-13 | New Life Resources, Llc | Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations |
US6946551B2 (en) | 2003-03-12 | 2005-09-20 | New Life Resources, Llc | Preparation of hyaluronic acid from eggshell membrane |
US20040180025A1 (en) * | 2003-03-12 | 2004-09-16 | New Life Resources, Llc | Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations |
US20050136126A1 (en) * | 2003-03-17 | 2005-06-23 | Cambridgemed, Inc. | Agent for reduction of scar formation by using wound alkalinization |
JP4212970B2 (en) * | 2003-06-30 | 2009-01-21 | 株式会社キーエンス | Safety relay system |
CA2532207A1 (en) * | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
US6913968B2 (en) * | 2003-07-30 | 2005-07-05 | International Business Machines Corporation | Method and structure for vertical DRAM devices with self-aligned upper trench shaping |
US8236794B2 (en) * | 2003-09-29 | 2012-08-07 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
JP2007507306A (en) * | 2003-09-30 | 2007-03-29 | ジンテーズ アクチエンゲゼルシャフト クール | Antimicrobial hyaluronic acid coating on orthopedic implants |
HUP0303313A2 (en) * | 2003-10-09 | 2005-07-28 | Richter Gedeon Vegyészeti Gyár Rt. | Transdermal pharmaceutical compositions |
WO2005044236A1 (en) * | 2003-10-27 | 2005-05-19 | Control Delivery Systems, Inc. | Suspension delivery system for the sustained and controlled local release of pharmaceuticals |
US20050100537A1 (en) * | 2003-11-10 | 2005-05-12 | Evans Gregory S. | Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals |
US20050147570A1 (en) * | 2004-01-06 | 2005-07-07 | Nordsiek Michael T. | Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne |
US20070053963A1 (en) * | 2004-01-13 | 2007-03-08 | Hotchkiss Robert N | Drug delivery to a joint |
DE102004002001A1 (en) * | 2004-01-14 | 2005-08-11 | Reinmüller, Johannes, Dr.med. | Agent for the treatment of inflammatory diseases |
US20050186269A1 (en) * | 2004-02-25 | 2005-08-25 | Udell Ronald G. | Stabilized feverfew formulations |
US8580315B2 (en) * | 2004-03-10 | 2013-11-12 | Esm Technologies, Llc | Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations |
US20060009693A1 (en) * | 2004-04-08 | 2006-01-12 | Techniscan, Inc. | Apparatus for imaging and treating a breast |
WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
AR051429A1 (en) * | 2004-04-20 | 2007-01-17 | Stenti De Pirillo Haydee A | OZONIZED PHARMACEUTICAL COMPOSITION AND METHODS TO OBTAIN IT |
CN1946906A (en) * | 2004-04-29 | 2007-04-11 | 吉斯通护岸系统股份有限公司 | Veneers for walls, retaining walls and the like |
CN101267828A (en) * | 2004-06-22 | 2008-09-17 | 普罗医药公司 | Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide |
DE102004030155B4 (en) * | 2004-06-22 | 2020-04-23 | Robert Bosch Gmbh | Metering device and method for operating the same |
WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020853A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
AU2005272578A1 (en) * | 2004-08-13 | 2006-02-23 | Angiotech International Ag | Compositions and methods using hyaluronic acid and hyluronidase inhibitors |
US7414021B2 (en) * | 2004-10-01 | 2008-08-19 | Vincent Carmine Giampapa | Method and composition for restoration of age related tissue loss in the face or selected areas of the body |
CN101115475A (en) | 2004-12-10 | 2008-01-30 | 塔利马治疗公司 | Compositions and methods for treating conditions of the nail unit |
US20060275230A1 (en) | 2004-12-10 | 2006-12-07 | Frank Kochinke | Compositions and methods for treating conditions of the nail unit |
US20060292250A1 (en) * | 2005-06-23 | 2006-12-28 | Suracell, Inc. | Supplement composition and method of use for enhancement of anti-inflammation process |
BRPI0613611A2 (en) * | 2005-07-22 | 2011-01-18 | Myriad Genetics Inc | high concentration drug formulations and dosage forms |
US7276257B2 (en) * | 2005-07-22 | 2007-10-02 | The Hong Kong University Of Science And Technology | Schisandrin B preparation |
EP1912658B1 (en) * | 2005-07-27 | 2017-01-25 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
US7323184B2 (en) * | 2005-08-22 | 2008-01-29 | Healagenics, Inc. | Compositions and methods for the treatment of wounds and the reduction of scar formation |
US20070048391A1 (en) * | 2005-08-23 | 2007-03-01 | Cambridgemed, Inc. | Composition for reduction of scar formation on wound scar |
US8319625B2 (en) * | 2005-09-01 | 2012-11-27 | Simplexgrinnell Lp | Fire alarm textual notification related application |
CA2621604A1 (en) * | 2005-09-07 | 2007-03-15 | Amo Regional Holdings | Bi-modal hyaluronate solution |
CA2621279C (en) | 2005-09-07 | 2016-06-14 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
US9492381B1 (en) | 2005-11-10 | 2016-11-15 | Reyn Pharma, Llc | Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis |
US8598144B1 (en) | 2005-11-10 | 2013-12-03 | Reyn Pharma, Llc | Method of administering hyaluronan formulation for the amelioration of osteoarthritis |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US20080033045A1 (en) * | 2006-07-07 | 2008-02-07 | Myriad Genetics, Incorporated | Treatment of psychiatric disorders |
US7722665B2 (en) * | 2006-07-07 | 2010-05-25 | Graft Technologies, Inc. | System and method for providing a graft in a vascular environment |
WO2008031194A1 (en) | 2006-09-13 | 2008-03-20 | Enhance Skin Products, Inc. | Cosmetic composition for the treatment of skin and methods thereof |
DK2074141T3 (en) * | 2006-09-22 | 2016-11-28 | Novo Nordisk As | The protease resistant insulin analogues. |
WO2008070118A1 (en) * | 2006-12-05 | 2008-06-12 | Landec Corporation | Drug delivery |
JP5481197B2 (en) * | 2006-12-26 | 2014-04-23 | ボミ・パテル・フラムローゼ | Skin whitening composition for hyperpigmented skin |
US8466128B2 (en) | 2007-01-30 | 2013-06-18 | Cypress Pharmaceuticals, Inc. | Hyaluronate compositions |
AU2008222592B2 (en) * | 2007-03-02 | 2013-09-26 | Detsamma Investments Pty Ltd | Compositions and methods for delivery of anti-cancer agents |
US20080268039A1 (en) * | 2007-03-06 | 2008-10-30 | Soft Gel Technologies, Inc. | Loquat compositions |
WO2008143901A2 (en) * | 2007-05-15 | 2008-11-27 | Techniscan, Inc. | Improved imaging system |
SI2211896T1 (en) | 2007-11-13 | 2018-04-30 | Meritage Pharma, Inc. | Compositions for the treatment of gastrointestinal inflammation |
US20090123551A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
US20090143343A1 (en) * | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
ITMI20080284A1 (en) * | 2008-02-22 | 2009-08-23 | Indena Spa | ANTI-HUMAN AGENTS WITH BENZOPHENANTRIDIN STRUCTURE AND FORMULATIONS THAT CONTAIN THEM |
EP2254905B1 (en) | 2008-03-14 | 2016-12-14 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
RU2571857C2 (en) | 2008-03-18 | 2015-12-20 | Ново Нордиск А/С | Acylated insulin analogues stabilised with respect to proteases |
US20090264392A1 (en) * | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
US8163716B1 (en) | 2008-06-30 | 2012-04-24 | Smith James D | Method of administering hyaluronan formulation for the amelioration of osteophytes |
US8178511B1 (en) | 2008-07-02 | 2012-05-15 | Smith James D | Method of administering hyaluronan formulation for the amelioration of osteopenia |
IT1397247B1 (en) * | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | NEW REGULATORY AGENTS OF CYTOKINIC ACTIVITY |
GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
US8273725B2 (en) | 2009-09-10 | 2012-09-25 | Genzyme Corporation | Stable hyaluronan/steroid formulation |
US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
EP2598139A4 (en) * | 2010-07-26 | 2013-12-25 | Chemotherapeutics Llc | Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments |
US8524662B2 (en) | 2010-12-28 | 2013-09-03 | Depuy Mitek, Llc | Compositions and methods for treating joints |
US8398611B2 (en) | 2010-12-28 | 2013-03-19 | Depuy Mitek, Inc. | Compositions and methods for treating joints |
US8455436B2 (en) | 2010-12-28 | 2013-06-04 | Depuy Mitek, Llc | Compositions and methods for treating joints |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US20130096081A1 (en) | 2011-06-03 | 2013-04-18 | Allergan, Inc. | Dermal filler compositions |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
TW201249843A (en) * | 2011-06-14 | 2012-12-16 | Univ Kaohsiung Medical | Processes for preparing amine salts of KMUP-3 and use thereof |
US8623839B2 (en) | 2011-06-30 | 2014-01-07 | Depuy Mitek, Llc | Compositions and methods for stabilized polysaccharide formulations |
LT2543357T (en) * | 2011-07-07 | 2018-06-11 | Holy Stone Healthcare Co.,Ltd. | Composition for use in treating and preventing inflammation related disorder |
US20150359798A1 (en) * | 2011-09-06 | 2015-12-17 | Jansfat Biotechnology Co., Ltd. | Piperazinyl derivative reduces high-fat diet-induced accumulation of fat in the livers, therapeutically |
EP2567697A1 (en) | 2011-09-12 | 2013-03-13 | Almirall, S.A. | Topical pharmaceutical compositions |
TWI466675B (en) * | 2011-09-16 | 2015-01-01 | Univ China Medical | Pharmaceutical composition for inhibiting inflammation |
GB201118198D0 (en) | 2011-10-21 | 2011-12-07 | Jagotec Ag | Improvements in or relating to organic compounds |
GB201118193D0 (en) | 2011-10-21 | 2011-12-07 | Jagotec Ag | Improvements in or relating to oranic compounds |
ES2885523T3 (en) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
RU2497201C1 (en) * | 2012-03-28 | 2013-10-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Method for dermal flap survival growth in reduced circulation with minoxidil |
RU2497200C1 (en) * | 2012-03-28 | 2013-10-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Method for pharmacological correction of sceletal muscle ischemia with minoxidil |
IN2014MN01886A (en) | 2012-04-18 | 2015-07-10 | Univ Ramot | |
ITPD20120173A1 (en) | 2012-05-31 | 2013-12-01 | Fidia Farmaceutici | "NEW HYDROPHOBIC PROTEIN RELEASE SYSTEM" |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
ITMI20121316A1 (en) | 2012-07-27 | 2014-01-28 | Altergon Sa | CONDROTIC COMPLEXES FOR TRANSCUTANEOUS ABSORPTION |
FR2994846B1 (en) | 2012-08-29 | 2014-12-26 | Vivacy Lab | COMPOSITION, STERILIZED, COMPRISING AT LEAST ONE HYALURONIC ACID AND MAGNESIUM ASCORBYL PHOSPHATE |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
FR3000670B1 (en) * | 2013-01-10 | 2015-02-27 | Oreal | SOOTHING COSMETIC COMPOSITION BASED ON SALICYLIC ACID. |
EP2968886A1 (en) | 2013-03-14 | 2016-01-20 | Hallux, Inc. | Method of treating infections, diseases or disorders of nail unit |
EP2981283A4 (en) | 2013-04-03 | 2017-07-05 | Cedars-Sinai Medical Center | Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity |
GR1008308B (en) | 2013-05-31 | 2014-10-02 | UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", | Local pharmaceutical and medi-tech compositions containing combinations of sucralfat, hyaluronic acid, arginine and one natural moistening factor |
KR101439032B1 (en) * | 2013-06-13 | 2014-09-05 | 동아에스티 주식회사 | Pharmaceutical composition containing piroxicam and hyaluronic acid for the treatment of osteoarthritis |
CN103330945B (en) * | 2013-07-16 | 2014-07-02 | 山东大学齐鲁医院 | Application of pingyangmycin combined with sodium hyaluronate in drug for treating lymphatic malformation |
CN103341157A (en) * | 2013-07-25 | 2013-10-09 | 山东大学齐鲁医院 | Application of pingyangmycin combined sodium hyaluronate in medicine for treating venous malformation |
KR20160065126A (en) | 2013-10-07 | 2016-06-08 | 노보 노르디스크 에이/에스 | Novel derivative of an insulin analogue |
MX2016014281A (en) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies. |
EP3160448A4 (en) | 2014-06-26 | 2018-11-14 | Ramot at Tel-Aviv University Ltd. | Liposomal formulations for delivery of nucleic acids |
US9682099B2 (en) | 2015-01-20 | 2017-06-20 | DePuy Synthes Products, Inc. | Compositions and methods for treating joints |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
PE20191205A1 (en) | 2016-12-16 | 2019-09-10 | Novo Nordisk As | PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN |
WO2019173261A1 (en) * | 2018-03-06 | 2019-09-12 | Samuel Asculai | Composition and method to treat cancer using hyaluronic acid |
CN109512825A (en) * | 2018-12-29 | 2019-03-26 | 江苏靶标生物医药研究所有限公司 | A kind of composition and its application of platinum-like compounds and Sodium Hyaluronate |
CN110467689A (en) * | 2019-09-09 | 2019-11-19 | 山东众山生物科技有限公司 | A kind of derivatives of hyaluronic acids and preparation method thereof |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0138572A2 (en) * | 1983-10-11 | 1985-04-24 | FIDIA S.p.A. | Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same |
EP0197718A2 (en) * | 1985-04-05 | 1986-10-15 | FIDIA S.p.A. | New medicaments for topical use |
EP0216453A2 (en) * | 1985-07-08 | 1987-04-01 | FIDIA S.p.A. | Esters of hyaluronic acid and their salts. |
EP0224987A2 (en) * | 1985-11-29 | 1987-06-10 | Biomatrix, Inc. | Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same |
JPS62240628A (en) * | 1986-03-26 | 1987-10-21 | Kao Corp | Endermic absorption promoter and external preparation containing same |
EP0245126A2 (en) * | 1986-05-07 | 1987-11-11 | Taro Ogiso | Percutaneous absorption preparation and process for preparing same |
US4711780A (en) * | 1984-06-11 | 1987-12-08 | Fahim Mostafa S | Composition and process for promoting epithelial regeneration |
EP0265116A2 (en) * | 1986-10-13 | 1988-04-27 | FIDIA S.p.A. | Cross-linked esters of hyaluronic acid |
EP0287210A2 (en) * | 1987-03-13 | 1988-10-19 | Medical Research International Limited | Therapeutic compositions |
EP0380367A1 (en) * | 1989-01-27 | 1990-08-01 | Stafford-Miller Ltd. | Compositions and method for the treatment of disease |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2583096A (en) * | 1949-01-15 | 1952-01-22 | Searle & Co | Process for the production of high viscosity hyaluronic acid |
GB769287A (en) * | 1954-08-18 | 1957-03-06 | American Home Prod | Preparation of partially depolymerized hyaluronic acid and therapeutic compositions thereof |
FR3715M (en) * | 1964-06-11 | 1965-11-29 | Lucien Nouvel | Improved antithermics and antirheumatic drugs. |
US3887703A (en) * | 1967-03-24 | 1975-06-03 | Oreal | Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions |
GB1283892A (en) * | 1970-06-08 | 1972-08-02 | Irwin Irville Lubowe | Improvements in and relating to medicinal compositions for application to the skin and/or hair |
DE2364373A1 (en) * | 1973-12-22 | 1975-07-10 | Hahn Carl Dr Gmbh | Pharmaceutical and/or cosmetic prepns. - contg. methyl-substd. xanthine, oestriol and/or a mucopolysaccharide |
US4141973A (en) * | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
US4282216A (en) * | 1977-04-20 | 1981-08-04 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
US4296104A (en) * | 1979-08-30 | 1981-10-20 | Herschler R J | Therapeutic dimethyl sulfoxide composition and methods of use |
US4272522A (en) * | 1979-10-15 | 1981-06-09 | Balazs Endre A | Method for stimulating phagocytic activity and synergistic compositions therefor |
US4303676A (en) * | 1980-03-21 | 1981-12-01 | Balazs Endre A | Hyaluronate based compositions and cosmetic formulations containing same |
JPS57183707A (en) * | 1981-05-02 | 1982-11-12 | Shiseido Co Ltd | Cosmetic |
US4684627A (en) * | 1981-09-08 | 1987-08-04 | Leveen Harry H | Treatment of cancer with phlorizin and its derivatives |
US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
US4582685A (en) | 1982-10-07 | 1986-04-15 | Helena Laboratories Corporation | Test kit for performing a medical test |
US4711884A (en) * | 1983-02-28 | 1987-12-08 | E. R. Squibb & Sons, Inc. | Thiazine and thiazepine containing compounds |
AU555747B2 (en) * | 1983-08-09 | 1986-10-09 | Cilco Inc. | Chondroitin sulfate and sodium hyaluronate composition |
AU570998B2 (en) * | 1983-09-07 | 1988-03-31 | Takeda Chemical Industries Ltd. | Topical steroid compositions for acne |
CA1295796C (en) * | 1984-03-27 | 1992-02-18 | Conrad Whyne | Biodegradable matrix and methods for producing same |
CH663353A5 (en) * | 1984-03-28 | 1987-12-15 | Joaquin Amat Larraz | AGENT AGAINST CANCER. |
US4716224A (en) * | 1984-05-04 | 1987-12-29 | Seikagaku Kogyo Co. Ltd. | Crosslinked hyaluronic acid and its use |
JPS6117A (en) * | 1984-06-11 | 1986-01-06 | Seikagaku Kogyo Co Ltd | Mucopolysaccharide-type cancer-metastatis suppressing agent |
US4735902A (en) * | 1984-10-23 | 1988-04-05 | Matti Siren | Stabilized composition containing inositoltriphosphate |
US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4636524A (en) * | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
DE3686275T2 (en) * | 1985-01-11 | 1993-03-18 | Teijin Ltd | PREPARED PRODUCTS WITH DELAYED RELEASE. |
JPS61233622A (en) * | 1985-04-09 | 1986-10-17 | Riken Vitamin Co Ltd | Eye lotion composition |
SE8501723L (en) * | 1985-04-09 | 1986-10-10 | Pharmacia Ab | PREPARATION TO BE USED IN TREATMENT OF LED INFLAMMATION |
US4725585A (en) * | 1985-04-26 | 1988-02-16 | Pharmacia Ab | Method of enhancing the host defense |
US4725852A (en) | 1985-05-09 | 1988-02-16 | Burlington Industries, Inc. | Random artificially perturbed liquid apparatus and method |
IT1214609B (en) * | 1985-05-17 | 1990-01-18 | Opocrin Spa | HEXOSAMINOGLICANS DEPOLYMERIZED SULPHATES FOR ANTI-THROMBOTIC, FIBRINOLITHIC, ANTI-INFLAMMATORY ACTIVITIES, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
EP0207638B1 (en) * | 1985-06-04 | 1990-12-19 | Teijin Limited | Sustained-release pharmaceutical preparation |
US4617319A (en) * | 1985-06-13 | 1986-10-14 | American Cyanamid Company | Method of treating multiple sclerosis |
FR2584606A1 (en) * | 1985-07-12 | 1987-01-16 | Dropic | USE OF POLY- AND OLIGOSACCHARIDES FOR THE PRODUCTION OF ACTIVE MEDICAMENTS IN THE PATHOLOGIES OF CONNECTIVE TISSUE |
IN166447B (en) * | 1985-11-27 | 1990-05-12 | Ethicon Inc | |
JP2604135B2 (en) * | 1986-02-28 | 1997-04-30 | ライオン株式会社 | Oral bone disease treatment |
US5262403A (en) * | 1986-03-10 | 1993-11-16 | Board Of Regents, The University Of Texas System | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II |
JPS62212335A (en) * | 1986-03-14 | 1987-09-18 | Mitsui Toatsu Chem Inc | 2-aryl-2-methylpropyl ether derivative and insecticide containing said derivative as active component |
JPS6345223A (en) * | 1986-04-04 | 1988-02-26 | Ueno Seiyaku Oyo Kenkyusho:Kk | Remedy for retrovirus disease |
EP0240098A3 (en) * | 1986-04-04 | 1989-05-10 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Oligo and polysaccharides for the treatment of diseases caused by retroviruses |
US4808576A (en) * | 1986-04-28 | 1989-02-28 | Mobay Corporation | Remote administration of hyaluronic acid to mammals |
EP0244178A3 (en) * | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraocular dosage compositions and method of use |
IT1189111B (en) * | 1986-05-08 | 1988-01-28 | Minnesota Mining & Mfg | RADIOGRAPHIC ELEMENTS WITH A REDUCED CROSS-OVER AND REDUCED RESIDUAL COLORING |
JPS62287041A (en) * | 1986-06-05 | 1987-12-12 | Kawasaki Steel Corp | Production of high-alloy steel sintered material |
US4946870A (en) * | 1986-06-06 | 1990-08-07 | Union Carbide Chemicals And Plastics Company Inc. | Delivery systems for pharmaceutical or therapeutic actives |
JPS6311678A (en) | 1986-06-30 | 1988-01-19 | Hitachi Chem Co Ltd | Electroless copper plating method |
JPH0725689B2 (en) * | 1986-10-07 | 1995-03-22 | 中外製薬株式会社 | Sustained-release preparation containing granulocyte colony-stimulating factor |
JPH07110349B2 (en) * | 1986-11-04 | 1995-11-29 | セイレイ工業株式会社 | Paddy sorting device |
NZ222695A (en) * | 1986-11-29 | 1990-03-27 | Ueno Seiyaku Oyo Kenkyujo Kk | Synergistic antiviral compositions |
EP0270319A3 (en) * | 1986-12-03 | 1990-03-28 | Logistics Data Systems, Inc. | Video c.a.d. system |
US5385938B1 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of using glycolic acid for treating wrinkles |
WO1988007060A1 (en) * | 1987-03-19 | 1988-09-22 | Arthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
EP0285357A3 (en) * | 1987-03-31 | 1989-10-25 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Control of retroviruses |
US4795741A (en) * | 1987-05-06 | 1989-01-03 | Biomatrix, Inc. | Compositions for therapeutic percutaneous embolization and the use thereof |
US5079236A (en) * | 1987-05-27 | 1992-01-07 | Hyal Pharmaceutical Corporation | Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use |
GB8713662D0 (en) * | 1987-06-11 | 1987-07-15 | Skandigen Ab | Hyaluronic acid derivatives |
GB8713747D0 (en) * | 1987-06-12 | 1987-07-15 | Unilever Plc | Skin treatment composition |
GB8715242D0 (en) * | 1987-06-29 | 1987-08-05 | Wood E M | Fenclofenac as immunosuppressant drug |
IL86933A (en) * | 1987-07-01 | 1993-07-08 | Genentech Inc | Method and therapeutic compositions for the prevention of fibrin deposition for adhesions |
US4900550A (en) * | 1987-08-19 | 1990-02-13 | Amy Allene Cosmetiques, Inc. | Skin care cosmetic regime |
ATE109970T1 (en) * | 1987-09-03 | 1994-09-15 | Univ Georgia Res Found | CYCLOSPORIN EYE REMEDY. |
DE3881615T2 (en) * | 1987-09-08 | 1993-09-23 | Takeda Chemical Industries Ltd | WATER-INSOLUBLE CYTOKINS. |
NZ226171A (en) * | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
HU203198B (en) * | 1987-10-26 | 1991-06-28 | Sandoz Ag | Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect |
JPH01151462A (en) * | 1987-12-09 | 1989-06-14 | Terumo Corp | Fluid for peritoneal perfusion |
DK505488D0 (en) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | MEDIUM AND USE OF SAME |
DK505588D0 (en) * | 1988-02-26 | 1988-09-09 | Jesper Hamburger | MEDIUM AND USE OF SAME |
US4943560A (en) * | 1988-04-06 | 1990-07-24 | Regents Of The University Of Minnesota | Solvent system for chronic vascular infusion of hydrophobic drugs |
JPH01265970A (en) * | 1988-04-19 | 1989-10-24 | Shiseido Co Ltd | Collagen water solution or water dispersion solution including hyaluronic acid |
US4840341A (en) | 1988-05-09 | 1989-06-20 | Hasegawa Gary K | Clip and holder |
IT1219587B (en) * | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES |
JPH01287041A (en) * | 1988-05-13 | 1989-11-17 | Rooman Kogyo:Kk | Sustained release preparation |
US5135915A (en) * | 1988-10-14 | 1992-08-04 | Genentech, Inc. | Method for the treatment of grafts prior to transplantation using TGF-.beta. |
DE3900198A1 (en) * | 1989-01-05 | 1990-07-12 | Merck Patent Gmbh | TOPIC APPLICABLE PHARMACEUTICAL PREPARATION |
US5156846A (en) * | 1989-02-23 | 1992-10-20 | University Of Utah | Percutaneous drug delivery system |
US4996193A (en) * | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
US5053222A (en) * | 1989-06-07 | 1991-10-01 | Shiseido Company Ltd. | Hair cosmetic composition |
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
US5095037B1 (en) * | 1989-12-21 | 1995-12-19 | Nissho Kk | Combined anti-inflammatory agent |
US5181276A (en) * | 1990-02-22 | 1993-01-26 | Baxter International Inc. | Infection resistant products |
US5290271A (en) * | 1990-05-14 | 1994-03-01 | Jernberg Gary R | Surgical implant and method for controlled release of chemotherapeutic agents |
US5091182A (en) * | 1990-07-23 | 1992-02-25 | Syntex (U.S.A.) Inc. | Dispensing units for ketorolac topical gel formlations |
US5234914A (en) * | 1991-06-11 | 1993-08-10 | Patent Biopharmaceutics, Inc. | Methods of treating hemorrhoids and anorecial disease |
EP0804931B1 (en) * | 1992-02-04 | 2003-05-07 | Baxter International Inc. | Peritoneal dialysis solutions and their use to minimize injury to mesothelial cells |
-
1989
- 1989-09-21 CA CA000612307A patent/CA1340994C/en not_active Expired - Lifetime
-
1990
- 1990-09-18 AU AU64330/90A patent/AU6433090A/en not_active Abandoned
- 1990-09-18 WO PCT/CA1990/000306 patent/WO1991004058A2/en active Search and Examination
- 1990-09-18 HU HU9007339A patent/HU220758B1/en unknown
- 1990-09-18 US US07/675,908 patent/US6069135A/en not_active Expired - Lifetime
- 1990-09-18 DK DK95100186T patent/DK0656213T3/en active
- 1990-09-18 RO RO148511A patent/RO112812B1/en unknown
- 1990-09-18 DK DK90914108T patent/DK0445255T4/en active
- 1990-09-18 JP JP51320490A patent/JP3256761B2/en not_active Expired - Lifetime
- 1990-09-18 AT AT95100186T patent/ATE227587T1/en not_active IP Right Cessation
- 1990-09-18 EP EP95100186A patent/EP0656213B1/en not_active Expired - Lifetime
- 1990-09-18 KR KR1019910700514A patent/KR920700697A/en active IP Right Grant
- 1990-09-18 SG SG1996002961A patent/SG49658A1/en unknown
- 1990-09-18 RU SU4895848/A patent/RU2146139C1/en active
- 1990-09-18 AT AT90914108T patent/ATE131068T1/en not_active IP Right Cessation
- 1990-09-18 CA CA002042034A patent/CA2042034A1/en not_active Abandoned
- 1990-09-18 EP EP90914108A patent/EP0445255B2/en not_active Expired - Lifetime
- 1990-09-18 DE DE69024039T patent/DE69024039T3/en not_active Expired - Lifetime
- 1990-09-18 ES ES95100186T patent/ES2186693T3/en not_active Expired - Lifetime
- 1990-09-18 BR BR909006924A patent/BR9006924A/en unknown
- 1990-09-18 ES ES90914108T patent/ES2080837T5/en not_active Expired - Lifetime
- 1990-09-18 DE DE69034018T patent/DE69034018T2/en not_active Expired - Lifetime
- 1990-09-19 IL IL9574590A patent/IL95745A/en active IP Right Grant
- 1990-09-21 SK SK4598-90A patent/SK459890A3/en unknown
- 1990-09-21 CN CN90108840A patent/CN1101228C/en not_active Expired - Lifetime
- 1990-09-21 IN IN821/CAL/90A patent/IN171745B/en unknown
- 1990-09-21 ZA ZA907564A patent/ZA907564B/en unknown
- 1990-09-21 AP APAP/P/1990/000206A patent/AP175A/en active
-
1991
- 1991-05-21 NO NO91911952A patent/NO911952L/en unknown
- 1991-05-21 FI FI912470A patent/FI912470A0/en unknown
-
1993
- 1993-12-09 AU AU52274/93A patent/AU674894C/en not_active Expired
- 1993-12-10 LT LTIP1582A patent/LT3545B/en unknown
-
1994
- 1994-08-05 US US08/286,263 patent/US5827834A/en not_active Expired - Lifetime
-
1995
- 1995-06-05 US US08/465,335 patent/US5811410A/en not_active Expired - Lifetime
- 1995-06-05 US US08/462,154 patent/US5985850A/en not_active Expired - Lifetime
- 1995-06-05 US US08/462,614 patent/US5914314A/en not_active Expired - Lifetime
- 1995-06-05 US US08/462,615 patent/US5830882A/en not_active Expired - Lifetime
- 1995-06-05 US US08/461,124 patent/US5932560A/en not_active Expired - Lifetime
- 1995-06-05 US US08/462,148 patent/US5929048A/en not_active Expired - Lifetime
- 1995-06-05 US US08/462,147 patent/US5852002A/en not_active Expired - Lifetime
- 1995-06-05 US US08/461,565 patent/US6048844A/en not_active Expired - Lifetime
- 1995-06-30 HU HU95P/P00656P patent/HU211953A9/en unknown
- 1995-08-07 US US08/460,978 patent/US6194392B1/en not_active Expired - Lifetime
-
1996
- 1996-11-18 US US08/744,852 patent/US5985851A/en not_active Expired - Lifetime
-
1997
- 1997-02-21 AU AU14850/97A patent/AU1485097A/en not_active Abandoned
- 1997-04-10 HK HK44797A patent/HK44797A/en not_active IP Right Cessation
-
1998
- 1998-06-10 HK HK98105089A patent/HK1005985A1/en not_active IP Right Cessation
-
2003
- 2003-07-28 US US10/628,999 patent/US20040019011A1/en not_active Abandoned
-
2005
- 2005-10-07 US US11/245,816 patent/US20060128655A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0138572A2 (en) * | 1983-10-11 | 1985-04-24 | FIDIA S.p.A. | Hyaluronic acid fractions having pharmaceutical activity, methods for preparation thereof, and pharmaceutical compositions containing the same |
US4711780A (en) * | 1984-06-11 | 1987-12-08 | Fahim Mostafa S | Composition and process for promoting epithelial regeneration |
EP0197718A2 (en) * | 1985-04-05 | 1986-10-15 | FIDIA S.p.A. | New medicaments for topical use |
EP0216453A2 (en) * | 1985-07-08 | 1987-04-01 | FIDIA S.p.A. | Esters of hyaluronic acid and their salts. |
EP0224987A2 (en) * | 1985-11-29 | 1987-06-10 | Biomatrix, Inc. | Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same |
JPS62240628A (en) * | 1986-03-26 | 1987-10-21 | Kao Corp | Endermic absorption promoter and external preparation containing same |
EP0245126A2 (en) * | 1986-05-07 | 1987-11-11 | Taro Ogiso | Percutaneous absorption preparation and process for preparing same |
EP0265116A2 (en) * | 1986-10-13 | 1988-04-27 | FIDIA S.p.A. | Cross-linked esters of hyaluronic acid |
EP0287210A2 (en) * | 1987-03-13 | 1988-10-19 | Medical Research International Limited | Therapeutic compositions |
EP0380367A1 (en) * | 1989-01-27 | 1990-08-01 | Stafford-Miller Ltd. | Compositions and method for the treatment of disease |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, vol. 76, no. 10, 6 March 1972, Columbus, Ohio, US; abstract no. 49897F, SNEADER W. E. ET AL: "Possible mechanism for the action of dimethyl sulfoxide on percutaneous absorption" page 273; * |
DATABASE WPI Derwent World Patents Index; AN 87-337226 * |
J. PHARM., PHAMACOL., vol. 23 SUPPL, 1971, pages 252S * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991004058A3 (en) | Treatment of conditions and disease | |
AU576365B2 (en) | Collagen and or fibrinogen as carrier of drugs for their introduction into cellular lesion areas | |
CA2314326A1 (en) | Transdermal therapeutic device and method with capsaicin and capsaicin analogs | |
EP0333606A3 (en) | Preparation of t-cell and t-cell membrane for use in prevention and treatment of autoimmune diseases | |
CS9004859A2 (en) | Method of adhesive plaster production that contains oestrogen as active substance | |
BR9306841A (en) | Pharmaceutical composition process for providing an antihistamine treatment which does not induce any significant cardiac arrhythmia in a human patient and use of a composition for the manufacture of a medicine for use in an antihistamine treatment | |
PH23867A (en) | Method of treating parkinson's disease using indolone derivatives | |
Petersen et al. | Chronic pain treatment with intravenous lidocaine | |
CA2214503A1 (en) | Method for treating tumors | |
WO2000021548A3 (en) | Angiogenically effective unit dose of fgf and method of administering | |
WO1999024074A3 (en) | Novel conjugates of opioids and endogenous carriers | |
EP1733734A3 (en) | Placental alkaline phosphatase to control diabetes | |
AU8091787A (en) | The use of paroxetine to treat pain | |
WO1996030042A3 (en) | Methods of treating inflammation and compositions therefor | |
EP1304108A3 (en) | Anti-arrhythmic composition and methods of treatment | |
GB9023701D0 (en) | Medical treatment | |
Jewell et al. | Heparin and ethyl biscoumacetate in prevention of experimental venous thrombosis | |
AU1656997A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer | |
AU6069794A (en) | Method and compositions for noninvasive dose to effect administration of lipophilic drugs | |
WO2000013701A3 (en) | Angiogenically effective unit dose of fgf-2 and method of use | |
NO965247L (en) | Use of cross-linked hemoglobin in the treatment of subarakuoid hemorrhage | |
GR3032224T3 (en) | Therapeutic agent for threatened abortion. | |
WO1997026880A3 (en) | Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients | |
SE8804640L (en) | MEDICINAL COMPREHENSIVE CYCLOLINOPEPTIDE A | |
ATE28384T1 (en) | MEDICAL PROCESS AND PREPARATION. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2042034 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990914108 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 912470 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1990914108 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 148511 Country of ref document: RO |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1990914108 Country of ref document: EP |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |